New Labeling Rules by FDA for Opioid Pain Meds

FDA has mandated safety label changes and post market study requirements for all extended-release and long-acting opioid pain medications. Among the changes is a warning to doctors that the drugs should only be prescribed for pain severe enough to require daily, around-the-clock, long-term treatment. A boxed warning also cautions that chronic maternal use of these products during pregnancy can result in neonatal opioid withdrawal syndrome.